Adverse functional, metabolic, or structural changes in ischemic tissues resulting from the restoration of blood flow to the tissue (reperfusion), including swelling; hemorrhage; necrosis; and damage ...
Comprehensive, easy-to-understand information about this condition
How we create this content →Report Generation Failed
We couldn't automatically generate the report. This may be due to temporary service issues.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease
ADIENNE S.A.
Other
Apeptico Forschung und Entwicklung GmbH (APEPTICO)
Other
Astellas Pharma Global Development, Inc.
Other
Bio-Technology General Corp.
Other
Borders Technology Management Ltd
Other
Corline Biomedical AB
Other
Digna Biotech, S.L.
Other
Endotis Pharma
Other
Hope Pharmaceuticals
Other
Institut Georges Lopez
Other
Neuramedy Co., Ltd.
Other
Nour Heart Therapeutics, LLC
Other
PharmaTher Inc.
Other
Revive Therapeutics Ltd.
Other
Sairiyo Therapeutics Inc.
Other
Y's Therapeutics, Inc.
Other
Young Therapeutics, LLC
Other
cellvie Inc.
Other
iCoat Medical AB
Other